NASDAQ · LENZ
LENZ Therapeutics, Inc.
Healthcare · Biotechnology
$3.08▲ 0.82% ($0.02)today
As of 3:01 PM ET
Market cap
$96.62M
P/E
N/M
EPS (TTM)
-$4.46
Next earnings
Valuation
Revenue & margin DCF
A cash-flow estimate wouldn't be reliable here
Every projected year produces negative free cash flow, so the model returns a negative enterprise value. A discounted-cash-flow valuation cannot be defended on those inputs, so it is not shown.
Only 2 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Annual revenue history contains a gap; multi-year changes are annualized over their actual fiscal-year span. Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.
1 more note
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
Data notes
Only 2 of the five annual revenue periods are available; growth uses the observed fiscal-year spans. Annual revenue history contains a gap; multi-year changes are annualized over their actual fiscal-year span. Latest quarterly growth differs materially from the latest annual pace. It remains an observed growth input; review whether acceleration or a change in the business explains it.
Reported operating earnings and the comparable cash-flow estimate differ substantially; the model retains the reported-margin anchor.
- 10-yr revenue CAGR
- 0.8%
- Ending operating margin
- 0.0%
- Discount rate
- 12.2%
USD · TTM ending Sep 30, 2026 · Price used $3.08 · Price Nov 2, 8:01 PM UTC
What each scenario assumes. Click a column to start from it.
Price vs Fundamentals
Why The Stock Is Moving
What changed
The stock fell 88.97% over the last year. Revenue declined 29.38% over the trailing twelve months. Operating margin moved from -388% to -1,211.17%.
What the market seems to be pricing
The market appears to be responding to weaker operating momentum rather than only rerating the stock.
What would invalidate this read
Operating margin stands at -1,211.17%. Revenue declined 29.38% — this read reverses if that trend stabilizes. If margins and cash flow stabilize while the stock stays depressed, the gap shifts from fundamental damage toward pure multiple compression.
Return analysis
Company profile
LENZ Therapeutics, Inc. is a biopharmaceutical firm whose primary mission involves the advancement and commercialization of new treatments designed to enhance vision for individuals in the United States.
Market multiples
Stock splits
Every 7 shares became 1
Profitability & growth
Analyst consensus
5
Buy
1
Hold
0
Sell
Analyst ratings tend to be lagging indicators. Use as one signal among many.
Earnings
Actuals vs estimates by quarter, or any quarter against the same one a year earlier.
Next report
Mar 23, 2027
Q4 FY26 · EPS est -$0.83 · Revenue est $4.2M
Q3 FY26
Reported Oct 29, 2026 · Latest
HoverTap a quarter to inspect
Actual
-$0.99
Estimate
-$0.89
Year over year
n/m
Vs prior quarter
n/m
1 beat · 3 misses in the last 4 quarters
Institutional Sentiment
LENZ Therapeutics, Inc. · LENZ
From Form 13F filings (managers with $100M+). Filings land up to 45 days after quarter end — read this as positioning context, not live fund flow.